THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to what action you should take, you are recommended to seek your own financial advice from your stockbroker or other independent adviser authorised under the Financial Services and Markets Act 2000.

If you have sold or transferred all of your shares in BATM Advanced Communications Ltd., please forward this document, together with the accompanying documents, as soon as possible either to the purchaser or transferee or to the person who arranged the sale or transfer so they can pass these documents to the person who now holds the shares.

Please note that this document sets out different voting processes for securities traded on the London Stock Exchange and for securities traded on the Tel-Aviv Stock Exchange. You must follow the correct process applicable to the securities you hold. If you hold multiple types of securities, you must follow a different process for each portion of your holding (see note 4 below in the Notes to the Notice of General Meeting for further information regarding the process).

BATM ADVANCED COMMUNICATIONS LTD.

Notice of General Meeting

of 24 September 2026

Chairman's letter

17 August 2026

Dear Shareholder,

General Meeting

I enclose a notice of the General Meeting (the "**GM**" or the "**Meeting**") of BATM Advanced Communications Ltd. (the "**Company**" or the "**Group**"), which is to be held at the Company's offices at 4 Ha'harash Street, Nave Ne'eman Industrial Area, P.O.B. 7318, 4524075 Hod Hasharon, Israel on 24 September 2026 at 12.00 p.m. Israel-time (10.00 a.m. UK-time) (the "**Notice**").

In order to enable shareholder engagement and participation for those unable to physically attend the Meeting, shareholders will be able to access the Meeting via videoconference.

PLEASE NOTE, shareholders will not be able to vote at the Meeting via the videoconference. Shareholders attending the Meeting via videoconference are therefore strongly encouraged to submit their vote in advance of the GM, in accordance with the Notes to the Notice of General Meeting set out below. To register to attend the GM via videoconference, please email yair.livneh@batm.com, stating your full name, at your earliest opportunity and no later than 7.30 p.m. Israel-time (5.30 p.m. UK-time) on 17 September 2026.

Background to the Meeting

Shareholders are asked to approve the transaction announced by the Company on 22 June 2026 and detailed in this Notice, under which the Group will sell three of its remaining four non-core activities, comprising seven corporate entities, to Mr. Haim Dor, for a cash consideration of $13.3m, and 96,794,500 ordinary shares of the Company held by a subsidiary will be sold to Mr. Dor at a price of 18.15p per ordinary share, equating to c. £17.6m. The aggregate cash consideration in respect of this transaction is approximately $36.6m (subject to fluctuations in the conversion rate). In addition, shareholders are requested to appoint Mr. Dor to the Board with effect from, and subject to, the completion of the transaction.

The transaction represents significant progress on the Group's strategy to exit its non-core activities, streamline its operations and concentrate resources on its core strengths of networking and cybersecurity. Following completion, only one non-core subsidiary would remain, being the Group's environmental monitoring company in Hungary, which the Board would consider selling should there be an appropriate opportunity. The transaction follows five other non-core disposals over the last 13 months, with the total cash to be generated from all of these non-core disposals being, in aggregate, over c. $40m, and the net proceeds will be deployed to drive growth in the Group's networking and cybersecurity activities. The Board believes that the sale of these businesses and shares is in the best interests of the Company and its shareholders as a whole. Full details are set out in the notes to this Notice and in Annex A.

Recommendation

The Board believes that the proposed resolutions are in the best interests of the Company and are most likely to promote the success of the Company for the benefit of its members as a whole, and recommends that you vote in favour of both proposed resolutions.

Yours sincerely,

Gil Sharon
Chairman

Notice is hereby given that a General Meeting (the "**GM**" or the "**Meeting**") of BATM Advanced Communications Ltd. ("BATM" or the "Company") will be held at the Company's offices at 4 Ha'harash Street, Nave Ne'eman Industrial Area, building E, 12th floor, Hod Hasharon, Israel on 24 September 2026 at 12.00 p.m. Israel-time (10.00 a.m. UK-time).

The purpose of the GM is to consider and, if thought fit, pass the resolutions detailed below.

RESOLUTIONS

<u>Sale of Non-Core Businesses and Company Shares to Mr. Haim Dor and Variation Authority</u>

1. To approve the transaction described in Note A below and in Annex A to this notice, in which the Group will sell to Mr. Haim Dor three of its remaining four non-core activities for a cash consideration of $13.3m, as well as 96,794,500 ordinary shares of the Company held by a subsidiary (which currently do not have any voting rights in accordance with section 309(b) of the Israeli Companies Law, and which as a result of the sale will regain their voting rights and will represent c. 22% of the Company's voting rights) at a price of 18.15p per ordinary share, including the authority of the Board until 31 December 2028 to approve variations of the payment terms in favour of the Group, within the limits and on the terms set out in the section titled "Terms of the Variation Authority" below, all as detailed in Note A.

<u>Election of Mr. Haim Dor to the Board of Directors of the Company</u>

2. To elect Mr. Haim Dor to the Board of Directors of the Company, subject to the completion of the Transaction (as defined in Note A), effective from the date of such completion until the following Annual General Meeting of the Company (Note B).

Dated: 17 August 2026

The resolutions are being proposed as ordinary resolutions.

<u>Explanatory Notes to the Resolutions</u>

Note A:

1. Resolution 1 seeks shareholder approval for the sale of three of the Group's remaining four non-core activities and of 96,794,500 ordinary shares of the Company held by a subsidiary, pursuant to two inter-conditional agreements entered into with Mr. Haim Dor and announced by the Company on 22 June 2026, including an authority for the Board, subject to the prior approval of the Audit Committee, to approve limited variations of the payment terms in favour of the Group (the "**Variation Authority**"), the terms of which are set out below and form an integral part of resolution 1.

2. On 22 June 2026, the Company announced that it had entered into a share purchase and loan assignment agreement (the "**SPLAA**") for the sale of three of its remaining four non-core activities, comprising seven corporate entities (the "**Disposed Businesses**"), for a cash consideration of $13.3m. In addition, Sunstring Limited ("**Sunstring**"), one of the Disposed Businesses, entered into a secondary share purchase agreement (the "**SSPA**") (together with the SPLAA, the "**Agreements**") for the sale of the 96,794,500 ordinary shares of NIS 0.01 each in the Company ("**Ordinary Shares**") held by Sunstring at a price of 18.15p per Ordinary Share, equating to a cash consideration of c. £17.6m (c. $23.3m at the time of the announcement). This represents a 33% premium to the average closing price of the Company's Ordinary Shares on the London Stock Exchange in the 30 trading days preceding the signing of the Agreements, and a 13% premium to the value of these shares on the completion of the transaction in which the Group received them in consideration for the sale of another non-core subsidiary, as previously announced.

3. The Agreements, which are inter-conditional, have been entered into with Mr. Haim Dor, with the aggregate cash consideration being approximately $36.6m (subject to fluctuations in the conversion rate) (the "**Transaction**"). The Disposed Businesses and the 96,794,500 Ordinary Shares (the "**Sale Shares**") will be sold to Mr. Dor (the "**Purchaser**"), who may assign his rights to entities owned or controlled by him.

4. Mr. Haim Dor is an entrepreneur and investor primarily focused on the private healthcare sector. Most notably, he was the founder and a significant shareholder of Raphael Hospitals Ltd. and played a leading role in the planning, establishment, and operation of Raphael Hospital in Tel Aviv. Mr. Dor is not a related party of the Group. Following completion of the Transaction, Mr. Dor will hold approximately 22% of the Company's issued share capital and voting rights. (See Note B for further detail.)

Background and rationale

5. The Transaction represents significant progress on the Group's strategy to exit its non-core activities, streamline its operations and concentrate resources on its core strengths of networking and cybersecurity. Following completion of the Transaction, only one non-core subsidiary would remain: the Group's environmental monitoring company in Hungary, which the Board would consider selling should there be an appropriate opportunity. This repositions BATM as a high-technology specialist delivering mission-critical secure managed networking, quantum encryption and cybersecurity solutions to governments, critical infrastructure providers and global enterprises ("**Continuing BATM**").

6. The Transaction will significantly accelerate the Group's strategy to become a streamlined company focused on the high-growth, high-margin and complementary markets of networking and cybersecurity. It follows five other non-core disposals over the last 13 months, with the total cash to be generated from all of these non-core disposals, including the Transaction and the sale of the Sale Shares, being, in aggregate, over c. $40m (subject to fluctuations in the conversion rate). The Board believes that the sale of the Disposed Businesses and the Sale Shares is in the best interests of the Group and its shareholders as a whole.

The Disposed Businesses

7. Summary information on the Disposed Businesses is as follows:

Name of entity	Country of incorporation	Principal activity	BATM ownership interest
Adaltis SRL	Italy	Medical diagnostics equipment	95.07%
Ador Diagnostics Ltd	Cyprus	Medical diagnostics IP company	41.30%
Einaudi 7	Italy	Real estate holding company	100.00%
I.M. Becor SRL	Moldova	Pharmaceutical product distribution	51.00%
I.M. Elodi-Farm SRL	Moldova	Pharmacy chain	51.00%
I.S.E. SRL	Italy	Medical diagnostics equipment	95.07%
Sunstring Ltd	Cyprus	Investment holding company	100.00%

8. For the financial year ended 31 December 2025, the Disposed Businesses (excluding Ador Diagnostics Ltd ("**ADOR**"), which is an associated company) generated revenue of $54.4m, adjusted operating profit of $2.2m, adjusted net profit of $0.4m and had net assets at year-end of $30.0m. In accordance with accounting standards, these figures reflect 100% of each entity's results as opposed to the percentage of 51.00% or more that corresponds with BATM's ownership interest. The Adjustments are the exclusion of the 1) exceptional contribution to the operating profit of Sunstring of the $14.1m capital gain from the sale during 2025 of the Group's diagnostics distribution business and 2) share of loss of a joint venture and associated companies and share of loss of financial balances of a joint venture and associated companies of $18.2m.

9. As set out in the Group's annual report and accounts for the year ended 31 December 2025, the Group's share of loss of a joint venture and associated companies and share of loss of financial balances of a joint venture and associated companies was $18.9m due to the strategic decision to write-off its investment in ADOR.

10. Further historical financial information on the Disposed Businesses, and the additional information required by Parts 2 and 3 of UKLR 7 Annex 2 of the UK Listing Rules, are set out in Annex A to this notice.

Summary of the terms of the Transaction

11. Under the terms of the SPLAA, the Group will sell its entire interest in the Disposed Businesses - comprising six subsidiaries and an associated company (and including the subsidiaries of the Disposed Businesses) - to the Purchaser. The Group will also transfer to the Purchaser its rights and title to certain shareholder loans between the Disposed Businesses and the Group.

12. The consideration to be paid by the Purchaser under the SPLAA is $13.3m, which values the Disposed Businesses at 33x their adjusted net profit for the year ended 31 December 2025 (adjusted as explained above), and which will be paid in three equal instalments, with the first instalment to be paid at the completion of the Transaction, the second instalment to be paid no later than 18 months after the completion of the Transaction and the third instalment no later than 24 months after the completion of the Transaction. The Group will contribute $3.18m towards existing overdue liabilities of the Disposed Businesses, which will be satisfied by a reduction of the three payment instalments. In addition, if the Purchaser sells all or any of the shares or assets of the Disposed Businesses within two years of the completion of the Transaction and the net proceeds received by the Purchaser exceed the price attributed to the entities and/or assets in the SPLAA plus interest and certain management fees, the Group would be entitled to receive 50% of the difference. This mechanism applies only to the Disposed Businesses and not to the Sale Shares.

13. Under the SSPA, Sunstring will sell the 96,794,500 Sale Shares to the Purchaser. The consideration to be paid by the Purchaser under the SSPA is 18.15p per Sale Share, totalling c. £17.6m, which is to be paid on completion in US dollars (with part of the sum to be paid in Israeli Shekels if the parties so agree at the time of payment) at the exchange rate prevailing on the day of payment.

14. The Purchaser has agreed to pledge the acquired ordinary shares of Sunstring (distinct from the Sale Shares) in favour of the Group, as a security in respect of the deferred instalments. The pledge shall be the sole security for the deferred payments, and the Group shall have no right of recourse against the Purchaser, subject to limited exceptions.

15. The Group has agreed to provide certain warranties and indemnities to the Purchaser in relation to the Disposed Businesses. In addition, should the Transaction complete, the Group will be bound by 24 months' non-compete and non-solicitation obligations in relation to the Disposed Businesses.

16. Sale of some of the Disposed Businesses was subject to rights of first refusal or tag along of minority shareholders in those businesses. The Company notified those minority shareholders of the Transaction. The Company has also provided those minority shareholders with further information, as requested by them, and set a final date for their election whether to exercise their rights. The minority shareholders made no such election until that final date. Following the passing of that final date, the Company informed them that, in the Company's view, the time for election has passed, that their rights of first refusal and of tag along are no longer capable of exercise, and that the Company is proceeding with the Transaction, reserving all of its rights.

17. The Transaction is conditional on a corporate reorganisation relating to holdings in the Disposed Businesses. Should the Group fail to perform such reorganisation within 150 days from signing of the Agreements, the Transaction may be terminated. The Transaction may also be terminated by either party in the event of a material breach by the other party, which is not cured within agreed timeframes.

18. There are no key individuals that are significant to Continuing BATM that are departing with the Disposed Businesses.

Conditions to completion

19. The completion of the Transaction is subject to shareholder approval, which is being sought pursuant to resolution 1, and all other customary legal and regulatory requirements. It is also subject to, and conditional upon, the simultaneous completion of both Agreements.

Terms of the Variation Authority (forming an integral part of resolution 1)

20. In approving resolution 1, the shareholders are requested to approve that the Board is authorised, subject to the prior approval of the Audit Committee, to agree with the Purchaser, at any time until 31 December 2028, and without further shareholder approval:

    - the acceleration of the payment date of any deferred instalment or part thereof or other amount payable to the Group under the Agreements, provided that any early-payment discount or other cost or concession borne by the Group in respect of such acceleration shall not exceed 5% of the amount so accelerated; and

    - an increase of up to 50% in the aggregate consideration payable to the Group;

    provided, in each case, that (i) the variation shall not increase any amount payable, or create any new obligation, by the Company or any of its subsidiaries to the Purchaser, and shall not waive or release any right of the Group under the Agreements (other than a pro-rata release of the pledge securing a deferred instalment upon its payment); and (ii) the Audit Committee and the Board shall have determined that the variation is in the best interests of the Company.

Background and rationale for the Variation Authority (explanatory only)

21. Under the Israeli Companies Law and the UK Listing Rules, an amendment of the Transaction terms agreed after completion could constitute a transaction with an interested or related party, requiring separate approvals. The authority is therefore sought so that the Board and the Audit Committee may agree, within the defined limits above, an earlier payment or an increase of amounts payable to the Group, without the cost and delay of a further general meeting. Any use of the authority will be announced in accordance with applicable law and the UK Listing Rules.

Use of net cash proceeds from the Transaction

22. The net proceeds of the Transaction will be deployed to drive growth in the Group's networking and cybersecurity activities. This includes via:

    - scaling the commercial pipeline by funding further proof-of-concepts with potential customers;
    - accelerating R&D programmes to maintain the Group's technological product lead and integrate its core platforms for an enhanced offer and operational efficiency;
    - investment in working capital to support anticipated growth; and
    - strategic and disciplined M&A, focused on providing access to market and customers.

Effects of the Transaction on the Group

23. The Transaction, based on the financial results for the year ended 31 December 2025, is expected to have the following financial impact on the Group:

- The Disposed Businesses' revenue of $54.4m in 2025 would no longer be contributing to the Group's results from the date of completion of the Transaction;

- The Disposed Businesses' adjusted (as described above) net profit of $0.4m in 2025 would no longer be contributing to the Group's results from the date of completion of the Transaction;

- The Disposed Businesses' total assets of $54.7m in 2025 would no longer be contributing to the Group's results from the date of completion of the Transaction; and

- The Disposed Businesses' total liabilities of $24.7m in 2025 would no longer be contributing to the Group's results from the date of completion of the Transaction.

24. In addition, following completion of the Transaction, the Group will have significantly streamlined its operations. It would have one remaining non-core subsidiary - namely, its environmental monitoring business in Hungary - which the Board would consider selling should there be an appropriate opportunity.

25. A description of the risks relating to the Transaction is set out in Appendix 1 (Additional Information) of the Company's announcement dated 22 June 2026, which is available on the Company's website.

Effects of the Transaction on total voting rights

26. In accordance with Israeli law, as the Sale Shares are currently held by a subsidiary of the Group (Sunstring), they do not have voting rights (section 309(b) of the Israeli Companies Law), and they currently represent c. 21.9% of the Company's issued share capital and 0% of the voting rights. As announced on 8 January 2026, following the transfer of the Sale Shares to Sunstring the Company's total voting rights were reduced to 340,079,684. As a result, on completion of the Transaction, the total number of Ordinary Shares with voting rights in the Company is expected to increase to 436,874,184 Ordinary Shares. This would be the figure used by shareholders as the denominator for the calculations by which they would determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

UK Listing Rules

27. Due to the size of the gross assets of the Disposed Businesses in relation to the gross assets of the Group, which exceeds 25%, the Transaction constitutes a significant transaction for the purposes of the UK Listing Rules of the Financial Conduct Authority (the "**UKLRs**") and is therefore notifiable in accordance with UKLR 7.3.1R and 7.3.2R. In accordance with the UKLRs, the Transaction is not subject to shareholder approval. However, to provide shareholders with the opportunity to exercise their right to inform corporate strategy, the Board has decided that the Transaction will be conditional, inter alia, upon approval by the Company's shareholders, which is being sought pursuant to resolution 1.

Majority required

28. Resolution 1 is being proposed as an ordinary resolution and requires a simple majority of the votes cast at the Meeting, in accordance with section 85 of the Israeli Companies Law and article 28.1.1 of the Company's Articles of Association. The Variation Authority, which forms an integral part of the resolution, is subject to the same majority requirement.

Note B:

29. The shareholders are requested to elect Mr. Haim Dor to the Board of Directors of the Company, subject to completion of the Transaction, and effective from the date of such completion until the following Annual General Meeting of the Company.

30. Mr. Dor has over 35 years' experience investing and developing companies across various industries. During the past 20 years, he has focused primarily on the healthcare sector. Over the last decade, Mr. Dor was the founder and a significant shareholder of Raphael Hospitals Ltd. He played a leading role in the planning, establishment, and operation of Raphael Hospital, which was founded in Tel Aviv as a modern and innovative institution combining advanced technologies, leading medical teams, and a broad range of surgical and medical services. Mr. Dor has extensive experience in strategic investments and business development, particularly within the healthcare sector.

31. The Board views the appointment of Mr. Dor to the Board of Directors of the Company as an integral part of the Transaction detailed in Note A.

32. Resolution 2 is being proposed as an ordinary resolution and requires a simple majority of the votes cast at the Meeting, in accordance with sections 59 and 85 of the Israeli Companies Law and article 39.1 of the Company's Articles of Association.

Dated: 17 August 2026

By order of the Board
Moti Nagar

Chief Executive Officer

Company number: 52-0042813

Registered office: 4 Ha'harash Street, Nave Ne'eman, PO
Box 7318, Hod Ha'sharon, 4524075 Israel.

Notes to the Notice of General Meeting

1. Only those members registered on the Company's register of members at close of business on 3 September 2026 (the "**Record Date**") shall be entitled to attend and vote at the Meeting.

2. Information regarding the Meeting is available and can be found on the Company's website at www.batm.com.

3. Quorum and adjourned meeting – the quorum shall be two or more shareholders present in person or by proxy. If such quorum is not present within one hour from the time scheduled for the Meeting, the Meeting will be adjourned for one week (to the same day, time and place). Any two members present in person or by proxy at the adjourned meeting, shall be deemed a quorum.

4. Enclosed with this document is (1) a form of proxy for holders of certificated securities admitted to trading on the London Stock Exchange (a "Form of Proxy"), (2) a form of direction for holders of uncertificated securities (i.e. Depositary Interests) representing ordinary shares admitted to trading on the London Stock Exchange (the "Form of Direction"), and (3) a form of proxy for holders of the Company's shares listed on the Tel-Aviv Stock Exchange (a "Form of Proxy to a TASE Member"). Please note that this document sets out different processes for securities admitted to trading on the London Stock Exchange and securities traded on the Tel-Aviv Stock Exchange. You must follow the correct process applicable to the securities you hold. If you hold multiple types of securities, you must follow a different process for each portion of your holdings.

5. **Shareholders holding through the London Stock Exchange** - If you are a member of the Company at the time set out in Note 1 above, you are entitled to appoint a proxy to exercise all or any of your rights at the Meeting. A proxy need not be a member of the Company but must attend the Meeting to represent you. Details of how to appoint your proxy are set out in the notes to the proxy form. **In order to be valid, proxy forms must be lodged at either MUFG Corporate Markets (the Company's registrar), at its address (MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, United Kingdom) or at the registered office of the Company in Israel marked for the attention of the CFO not less than 48 hours prior to the Meeting. A Form of Proxy appears below. Alternatively, you may submit your proxy electronically via the Investor Centre, a free app provided by MUFG Corporate Markets.** It allows you to securely manage and monitor your shareholdings in real time, take part in online voting, keep your details up to date and more. The same voting deadline of 48 hours before the time of the Meeting applies. The app is available to download on both the Apple App Store and Google Play, or by scanning the relevant QR code below, or can be accessed via a web browser at: https://uk.investorcentre.mpms.mufg.com/. If you need help with voting online, please contact our registrar, MUFG Corporate Markets, by email at shareholderenquiries@cm.mpms.mufg.com, or on 0371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 9.00 a.m. – 5.30 p.m., Monday to Friday excluding public holidays in England and Wales.

Download on the App Store

GET IT ON Google Play

6. In the case of a member which is a corporation, the proxy (or any related document) should be given under its common seal or under the hand of an officer or attorney duly authorised in writing. Any power of attorney or any other authority under which the Form of Proxy is signed (or a duly certified copy of such party or authority) must be included with the Form of Proxy.

7. In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding (the first-named being the most senior).

8. A corporation which is a shareholder can appoint one or more corporate representatives who may exercise, on its behalf, all its powers as a shareholder provided that no more than one corporate representative exercises powers over the same share.

9. To change your proxy instructions, simply submit a new proxy appointment using the methods set out above. Note that the cut-off time for receipt of proxy appointments (see above) also applies in relation to amended instructions. Any amended proxy appointment received after the relevant cut-off time will be disregarded.

   If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence.

   In order to revoke a proxy instruction, you will need to inform the Company by sending a hard copy notice clearly stating your intention to revoke your proxy appointment to MUFG Corporate Markets at the address referred to above. The revocation notice must be received by MUFG Corporate Markets not less than 48 hours prior to the Meeting.

10. A vote withheld is not a vote in law, which means that the vote will not be counted in the calculation of votes for or against the resolution. If you either select the "Discretionary" option or if no voting indication is given, your proxy will vote or abstain from voting at his or her discretion. Your proxy will vote (or abstain from voting) as he or she thinks fit in relation to any other matter that is put before the Meeting.

11. In the case of holders of Depositary Interests representing shares in the Company, a Form of Direction must be completed in order to direct MUFG Corporate Markets Trustees (Nominees) Limited, the Depositary, to vote on the holder's behalf at the Meeting (in person or by proxy) or, if the Meeting is adjourned, at the adjourned meeting. **In order to be effective, a completed and signed Form of Direction (and any power of attorney or other authority under which it is signed) must be delivered to MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, United Kingdom by no later than 72 hours before the time fixed for the Meeting or any adjourned meeting.** A Form of Direction appears below.

12. If you are a holder of Depositary Interests, your shares are held on your behalf in the name of MUFG Corporate Markets Trustees (Nominees) Limited, who are the registered shareholder. You can tell them how you want the votes in respect of your shares to be cast at the meeting and any adjournment(s) thereof, by utilising the CREST electronic proxy appointment service as per the procedures described in the CREST Manual (available from www.euroclear.com). CREST personal members or other CREST sponsored members, and

those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

In order for an instruction made using the CREST service to be valid, the appropriate CREST message (a CREST Proxy Instruction) must be properly authenticated in accordance with Euroclear UK & International Limited's specifications and must contain the information required for such instruction, as described in the CREST Manual (available via www.euroclear.com). The message, regardless of whether it constitutes a new instruction or is an amendment to the instruction given previously must, in order to be valid, be transmitted so as to be received by the Company's registrars (ID: RA10) by no later than 72 hours before the time fixed for the Meeting or any adjourned meeting. For this purpose, the time of receipt will be taken to be the time (as determined by the time stamp applied to the message by the CREST Application Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time, any change of instructions through CREST should be communicated to the Depositary through other means.

CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear UK & International Limited does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings (www.euroclear.com).

The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001 (as amended).

13. The Depository will appoint the Chair of the meeting as its proxy to cast its votes. The Chair of the meeting may also vote or abstain from voting as they think fit on any other business (including amendments to resolutions) which may properly come before the meeting. The 'Abstain' option is provided to enable you to abstain from voting on the resolution. However, it should be noted that an 'Abstain' is not a vote in law and will not be counted in the calculation of the proportion of the votes 'For' and 'Against' a resolution.

14. Depository interest holders wishing to attend the meeting should contact the Depository at MUFG Corporate Markets, Central Square, 29 Wellington Street, Leeds, LS1 4DL or by emailing Nominee.Enquiries@cm.mpms.mufg.com by no later than 72 hours before the time fixed for the Meeting or any adjourned meeting.

15. **Shareholders holding through the TASE** - Shareholders may vote their shares by appointing the TASE Member (bank, broker or other nominee that is admitted as a member of the TASE) through which they hold their shares as "proxies" to vote on their behalf, and they must direct the TASE Member on how to vote their shares. A duly executed Form of Proxy must be received by the TASE Member no later than 10.00 a.m. (Israel-time) on 17 September 2026, in order to be counted in the vote to be held in the Meeting. A shareholder's returned proxy may be revoked at any time prior to its exercise by giving written notice to the TASE Member of such revocation, sending a duly executed Form of Proxy bearing a

later date, no later than 10.00 a.m. (Israel-time) on 17 September 2026, requesting the return of the original Form of Proxy. The vote at the Meeting shall be carried out by the TASE Clearing House. The TASE Member shall direct the TASE Clearing House on how to vote the shares held by it, according to the TASE Clearing House by-laws, and submit to the TASE Clearing House a summary of the final results of all the proxies received by it and which it requests the TASE Clearing House to vote in its name, including the information required in the Form of Proxy regarding personal interests of the shareholders, if they are senior officers in the Company or controlling shareholders in the Company or a foreign institutional client, joint investment fund manager or trust fund, by no later than 2.00 p.m. (Israel-time) on 17 September 2026. A shareholder whose ordinary shares are registered with a TASE Member and are not registered on the Company's shareholder register is entitled to receive from the TASE Member who holds the ordinary shares on the shareholder's behalf, by email, for no charge, a link to the text of the Form of Proxy and to the position statements posted on the Israel Securities Authority website unless the shareholder has notified that he or she is not so interested; provided that the notice was provided with respect to a particular securities account prior to the Record Date. Beneficial owners who hold ordinary shares through TASE Members, or the TASE, would ordinarily be able to attend the Meeting by presenting a certificate signed by the TASE Member through which the shares are held, which complies with the Israel Companies Regulations (Proof of Ownership for Voting in General Meetings)-2000 as proof of ownership of the shares, or they may send such certificate to the Company's registered office prior to the Meeting. However, beneficial owners who hold ordinary shares through TASE Members will not be able to vote at the Meeting in person and will have to follow the voting instructions detailed in this sub-section 15 and in the Form of Proxy.

16. Appointment of a proxy does not preclude you from attending the Meeting and voting in person (except for shareholders whose shares are listed on the TASE, to whom sub-section 15 herein shall apply).

17. The Company will answer at the Meeting any question you submit in advance as detailed above relating to the business being dealt with unless:

    17.1 answering the question would interfere unduly with the preparation for the Meeting or involve the disclosure of confidential information;

    17.2 the answer has already been given on a website in the form of an answer to a question; or

    17.3 it is undesirable in the interest of the Company or the good order of the Meeting that the question be answered.

18. As at 16 August 2026, the Company's issued share capital comprised 441,369,184 ordinary shares of 0.01 NIS each, including 96,794,500 ordinary shares held by a subsidiary of the Company (which do not have any voting rights in accordance with section 309(b) of the Israeli Companies Law) and 4,495,000 ordinary shares held in treasury. Each ordinary share (other than those held by such subsidiary or in treasury) carries the right to one vote at a general meeting of the Company and, therefore, the total number of voting rights in the Company as at 16 August 2026 is 340,079,684.

19. If you hold securities traded on the London Stock Exchange and do not have a Form of Proxy or Form of Direction and believe that you should have one, or if you require additional forms, please contact MUFG Corporate Markets via email at

shareholderenquiries@cm.mpms.mufg.com or on 0371 664 0300 if calling from the UK (calls are charged at the standard geographic rate and will vary by provider) or +44 (0)371 664 0300 if calling from outside the UK.

20. You may not use any electronic address provided either:

    20.1 in this notice of General Meeting; or

    20.2 any related documents (including the Chairman's letter and proxy forms)

    to communicate with the Company for any purposes other than those expressly stated.

21. Information concerning the Company may be found on its website at www.batm.com.

22. The following documents will be available for inspection at **the registered office of the Company** from 17 August 2026 until the time of the Meeting and at the Meeting venue itself for at least 15 minutes prior to the Meeting until the end of the Meeting:

    - A copy of the current Company's articles of association

[THIS PAGE IS INTENTIONALLY LEFT BLANK]

Form of Proxy

(for holders of securities listed on the London Stock Exchange)

For use at the General Meeting
of BATM Advanced Communications Ltd. To be convened
At 12.00 p.m. Israel-time (10.00 a.m. UK-time) on 24 September 2026 at the Company's offices at 4 Ha'harash Street, Nave Ne'eman Industrial Area, building E, 12th floor, Hod Hasharon, Israel

I/We …………………………………………………………………………………

of …………………………………………………………………………………

being a member of the Company hereby appoint ……………………….…………/ the Chairman of the meeting to act as my/our proxy and to vote for me/us as indicated below with an "X" at the General Meeting of the Company convened for 24 September 2026 at 12.00 p.m. Israel-time (10.00 a.m. UK-time) and at any adjournment.

Date …………………………… Signed ……………………………

Please indicate how you wish to vote with an "X" in the appropriate box opposite each resolution. If no specific indication as to voting is given, the proxy will vote or abstain in their own direction as they will on any other matter arising at the meeting.

No.	**Resolution**	**Your vote**		
		For	**Against**	**Abstain**
1.	To approve the transaction in which the Group will sell to Mr. Haim Dor non-core activities as well as 96,794,500 ordinary shares of the Company including the Variation Authority			
2.	To elect Mr. Haim Dor to the Board subject to the completion of the transaction and effective from the date of such completion			

Notes:

1. This Form of Proxy to be valid must be completed and signed and must be deposited with MUFG Corporate Markets to its address (at **MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, United Kingdom**) or at the registered office of the Company not less than 48 hours before the time fixed for the meeting.

   Alternatively, you may submit your proxy electronically using the Investor Centre app or at https://uk.investorcentre.mpms.mufg.com/. Shareholders can use this service to vote or appoint a proxy online.

2. In the case of a corporation, this proxy should be under its common seal, or if not so required, under the hand of an officer duly authorised in writing.
3. In the case of joint holders, the signature of any one of them will suffice but the vote of the senior who tenders a vote whether in person or by proxy will be accepted to the exclusion of the votes of the other joint holders and for this purpose, seniority shall be determined by the order in which the names stand on the Company's register of members in respect of the joint holding.
4. Any alteration made in the form of proxy should be initialled.
5. By voting using this Form of Proxy you are declaring that you have no personal interest (as defined in Israeli Companies Law) in the approval of any of the resolutions except a personal interest of which, if applicable, you have specifically informed the Company. In accordance with Israeli Companies Law, a 'personal interest' is deemed to be a personal interest in the engagement contemplated by the relevant resolution, including the interest of certain family relatives and of corporations affiliated to any person having such interest, but excluding a personal interest stemming from the fact of a shareholding in the Company.
6. You are referred to the Notes to the Notice of General Meeting for further information.

Form of Direction

For use by holders of Depositary Interests representing shares on a one-for-one basis in BATM Advanced Communications Ltd. ("BATM") in respect of the General Meeting of BATM to be convened on 24 September 2026 at 12.00 p.m. Israel-time (10.00 a.m. UK-time) at the Company's offices at 4 Ha'harash Street, Nave Ne'eman Industrial Area, building E, 12th floor, Hod Hasharon, Israel

I/We ………………………………………………………………………………………

of …………………………………………………………………………………………

being a holder of Depositary Interests representing shares in BATM hereby direct MUFG Corporate Markets Trustees (Nominees) Limited, the Depositary, to vote for me/us and on my/our behalf in person or by proxy at the General Meeting of BATM to be held on the above date (and at any adjournment thereof) as directed by an "X" in the appropriate box opposite each resolution. **If no indication is given, you will be deemed as instructing the Depositary to abstain from voting.**

No.	**Resolution**	**Your vote**		
		For	**Against**	**Abstain**
1.	To approve the transaction in which the Group will sell to Mr. Haim Dor non-core activities as well as 96,794,500 ordinary shares of the Company including the Variation Authority			
2.	To elect Mr. Haim Dor to the Board subject to the completion of the transaction and effective from the date of such completion			

Signature: ………………………………….. Date: ……………………

Notes:

1. To be effective, this Form of Direction and the power of attorney or other authority (if any) under which it is signed, or a notarised or otherwise certified copy of such power of attorney, must be deposited at MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, United Kingdom not later than 72 business hours before the time appointed for holding the meeting.
2. Any alterations made to this Form of Direction should be initialled.
3. In the case of a corporation, this Form of Direction should be given under its common seal or under the hand of an officer or attorney duly authorised in writing.

4. Please indicate how you wish your votes to be cast by placing "X" in the boxes provided. On receipt of this form duly signed, you will be deemed to have authorised MUFG Corporate Markets to vote as per your instructions.
5. The Depositary will appoint the Chairman of the meeting as its proxy to cast your votes. The Chairman may also vote or abstain from voting as he or she thinks fit on any other resolution (including amendments to resolutions) that may properly come before the meeting.
6. If a Depositary Interest holder wishes to attend the General Meeting, they should notify MUFG Corporate Markets (the Depositary) accordingly who will issue a Letter of Representation to the Depositary Interest holder giving them authorisation to attend the General Meeting. If any Depositary Interest holder attends the General Meeting without a Letter of Representation, they will only be allowed to enter the General Meeting as a guest. Requests for a Letter of Representation should be made to the Depositary at MUFG Corporate Markets, Central Square, 29 Wellington Street, Leeds LS1 4DL, United Kingdom or by email to Nominee.Enquiries@cm.mpms.mufg.com no later than 72 business hours prior to the meeting or any adjourned meeting.
7. By voting using this Form of Direction you are declaring that you have no personal interest (as defined in Israeli Companies Law) in the approval of any of the resolutions except a personal interest of which, if applicable, you have specifically informed the Company. In accordance with Israeli Companies Law, a 'personal interest' is deemed to be a personal interest in the engagement contemplated by the relevant resolution, including the interest of certain family relatives and of corporations affiliated to any person having such interest, but excluding a personal interest stemming from the fact of a shareholding in the Company.
8. Depositary Interest Holders may also vote through the CREST Proxy Voting Service in accordance with the procedures set out in the CREST manual.
9. You are referred to the Notes to the Notice of General Meeting for further information.

Form of Proxy

For Holders of Shares Listed on the Tel-Aviv Stock Exchange

For use at the General Meeting
of BATM Advanced Communications Ltd, Israeli company no. 520042813,
to be convened at 12.00 p.m. Israel-time (10.00 a.m. UK-time) on 24 September 2026 at the Company's offices at 4 Ha'harash Street, Nave Ne'eman Industrial Area, building E, 12th floor, Hod Hasharon, Israel

I/We …………………………………………………………………………………

ID / company number ……………………………………………………………………

being a holder of share(s) of the Company listed on the Tel-Aviv Stock Exchange and entitled to attend and vote hereby appoint ………………………………..………… (the "TASE Member") to vote on my behalf in person or by proxy as indicated below with an "X" at the General Meeting of the Company convened for 24 September 2026 at 12.00 p.m. Israel-time (10.00 a.m. UK-time) and at any adjournment thereof.

Date …………………………… Signed ……………………………

Please indicate how you wish to vote with an "X" in the appropriate box opposite each resolution. If no specific indication as to voting is given, the TASE Member (or his proxy) will vote or abstain in their own direction as they will on any other matter arising at the meeting.

No.	**Resolution**	**Your vote**		
		For	**Against**	**Abstain**
1.	To approve the transaction in which the Group will sell to Mr. Haim Dor non-core activities as well as 96,794,500 ordinary shares of the Company including the Variation Authority			
2.	To elect Mr. Haim Dor to the Board subject to the completion of the transaction and effective from the date of such completion			

Notes:

1. For this Form of Proxy to be valid, the broker, bank or other nominee company through which the shareholder holds their shares must receive, by no later than 10.00 a.m. (Israel-time) on 17 September 2026, a legible PDF scan of the duly completed and signed Form of Proxy.

2. In the case of a corporation, this proxy should be under its common seal, or if not so required, under the hand of an officer duly authorised in writing.
3. In the case of joint holders, the signature of any one of them will suffice but the vote of the senior who tenders a vote whether in person or by proxy will be accepted to the exclusion of the votes of the other joint holders and, for this purpose, seniority shall be determined by the order in which the names stand on the Company's register of members in respect of the joint holding.
4. The TASE Member or their proxy will appoint the Chairman of the meeting as their proxy to cast your votes. The Chairman may also vote or abstain from voting as he or she thinks fit on any other resolution (including amendments to resolutions) that may properly come before the meeting.
5. Any alteration made in the Form of Proxy should be initialled.
6. By voting using this Form of Proxy you are declaring that you have no personal interest (as defined in Israeli Companies Law) in the approval of any of the resolutions except a personal interest of which, if applicable, you have specifically informed the Company. In accordance with Israeli Companies Law, a 'personal interest' is deemed to be a personal interest in the engagement contemplated by the relevant resolution, including the interest of certain family relatives and of corporations affiliated to any person having such interest, but excluding a personal interest stemming from the fact of a shareholding in the Company.
7. You are referred to the Notes to the Notice of General Meeting for further information.

Annex A

Appendix 1 – Historical Financial Information

The following historical financial information relating to the Disposed Businesses has been extracted without material adjustment from the consolidation schedules and supporting accounting records that underlie the audited consolidated financial statements of the Group for the years ended 31 December 2024 and 31 December 2025. There have been no changes to the accounting policies applicable to this information in those periods.

Consolidated balance sheet of the Disposed Businesses

(US$m)	As at 31 December	
	2025	2024
Current assets	41.9	35.2
Non-current assets	12.8	25.8
Current liabilities	(21.2)	(17.6)
Non-current liabilities	(3.5)	(3.6)

Consolidated statement of profit or loss of the Disposed Businesses

(US$m)	Year ended 31 December	
	2025	2024
Revenue	54.4	49.3
Adj. operating profit/(loss)*	2.2	(2.8)
Adj. net profit*	0.4	(4.3)

* 2025 figures adjusted to exclude the 1) exceptional contribution to the operating profit of Sunstring of the $14.1m capital gain from the sale during 2025 of the Group's diagnostics distribution business, A.M.S 2000 Trading Impex SRL ("AMS") and 2) share of loss of a joint venture and associated companies and share of loss of financial balances of a joint venture and associated companies of $18.2m. 2024 figures include an expense of $3.3m due to the write-off of goodwill and intangible assets.

Ador Diagnostics Ltd

ADOR Diagnostics Ltd ("ADOR") is an associate company of the Group. The Group's share of loss for ADOR during the years ended 31 December 2024 and 2025 are below. The results for 2025 reflect the write-off of the Group's total investment in, and its financial balances with, ADOR, which amounted to $18.7m.

(US$m)	Year ended 31 December	
	2025	2024
Share of loss of ADOR, an associated company	(17.0)	(0.2)
Share of loss of financial balances of ADOR, an associated company	(1.7)	-

$18.2m of the expense due to the write off of the Group's investment in ADOR was recognised by one of the Disposed Businesses, being the entity that directly holds the shares in ADOR, and the remaining $0.5m was recognised by Continuing BATM.

Appendix 2 – Additional Information

1. Details of any legal and arbitration proceedings

1.1 Continuing BATM

There are no governmental, legal or arbitration proceedings (including any such proceedings which are pending or threatened of which the Group is aware) during the period covering the 12 months prior to the date of this announcement which may have, or have had in the recent past, a significant effect on the financial position or profitability of the Group and/or Continuing BATM, other than a claim regarding discontinued operations that was filed on 2019 and decided and paid on 2025, as detailed in note 20 of the 2025 annual financial statements.

1.2 Disposed Businesses

There are no governmental, legal or arbitration proceedings (including any such proceedings which are pending or threatened of which the Group is aware) during the period covering the 12 months prior to the date of this announcement which may have, or have had in the recent past, a significant effect on the Disposed Businesses' financial position or profitability.

2. Material contracts

2.1 Continuing BATM

Other than as disclosed in the annual report and accounts for the years ended 31 December 2024 and 31 December 2025, or as set out below, there are no contracts that have been entered into by the Group or Continuing BATM (not being contracts entered into in the ordinary course of business): (i) within the period of two years immediately preceding the date of this announcement that are, or may be, material to Continuing BATM; or (ii) that contain any provisions under which the Group or Continuing BATM has any obligation or entitlement that is material to Continuing BATM.

(a) Agreements in relation to the Transaction

A summary of the principal terms of the Transaction is set out in the Group's announcement dated 22 June 2026.

2.2 Disposed Businesses

Other than as disclosed in the annual report and accounts for the years ended 31 December 2024 and 31 December 2025, or as set out below, there are no contracts that have been entered into by the Disposed Businesses (not being contracts entered into in the ordinary course of business): (i) within the period of two years immediately preceding the date of this announcement that are, or may be, material to the Disposed Businesses; or (ii) that contain any provisions under which the Disposed Businesses has any obligation or entitlement that is, or may be, material to the Disposed Businesses.

(a) Agreements in relation to the Transaction

A summary of the principal terms of the Transaction is set out in the Group's announcement dated 22 June 2026.

3. Significant change in financial position

3.1 Continuing BATM

There has been no significant change in the financial performance or financial position of Continuing BATM since 31 December 2025, the end of the last financial period for which financial information of

Continuing BATM has been published.

3.2 Disposed Businesses

There has been no significant change in the financial performance or financial position of the Disposed Businesses since 31 December 2025, the end of the last financial period for which financial information of the Disposed Businesses has been published, except for Sunstring. Subsequent to 31 December 2025, Sunstring sold Laborator AMS for a cash consideration of $1m. The proceeds of the sale were received by Continuing BATM, as the parent company.

4. Related Party Transactions

Other than those matters disclosed in previously published annual reports and accounts of the Group and/or otherwise disclosed in this announcement (including its Appendices), there were no related party transactions entered into by the Group during the period from 31 December 2025 until the date of this announcement.